Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Oct 23;3(5):e001060.
doi: 10.1161/JAHA.114.001060.

Multilocus genetic risk scores for venous thromboembolism risk assessment

José Manuel Soria  1 , Pierre-Emmanuel Morange  2 , Joan Vila  3 , Juan Carlos Souto  4 , Manel Moyano  5 , David-Alexandre Trégouët  6 , José Mateo  4 , Noémi Saut  6 , Eduardo Salas  5 , Roberto Elosua  7
Affiliations
Comparative Study

Multilocus genetic risk scores for venous thromboembolism risk assessment

José Manuel Soria et al. J Am Heart Assoc. .

Abstract

Background: Genetics plays an important role in venous thromboembolism (VTE). Factor V Leiden (FVL or rs6025) and prothrombin gene G20210A (PT or rs1799963) are the genetic variants currently tested for VTE risk assessment. We hypothesized that primary VTE risk assessment can be improved by using genetic risk scores with more genetic markers than just FVL-rs6025 and prothrombin gene PT-rs1799963. To this end, we have designed a new genetic risk score called Thrombo inCode (TiC).

Methods and results: TiC was evaluated in terms of discrimination (Δ of the area under the receiver operating characteristic curve) and reclassification (integrated discrimination improvement and net reclassification improvement). This evaluation was performed using 2 age- and sex-matched case-control populations: SANTPAU (248 cases, 249 controls) and the Marseille Thrombosis Association study (MARTHA; 477 cases, 477 controls). TiC was compared with other literature-based genetic risk scores. TiC including F5 rs6025/rs118203906/rs118203905, F2 rs1799963, F12 rs1801020, F13 rs5985, SERPINC1 rs121909548, and SERPINA10 rs2232698 plus the A1 blood group (rs8176719, rs7853989, rs8176743, rs8176750) improved the area under the curve compared with a model based only on F5-rs6025 and F2-rs1799963 in SANTPAU (0.677 versus 0.575, P<0.001) and MARTHA (0.605 versus 0.576, P=0.008). TiC showed good integrated discrimination improvement of 5.49 (P<0.001) for SANTPAU and 0.96 (P=0.045) for MARTHA. Among the genetic risk scores evaluated, the proportion of VTE risk variance explained by TiC was the highest.

Conclusions: We conclude that TiC greatly improves prediction of VTE risk compared with other genetic risk scores. TiC should improve prevention, diagnosis, and treatment of VTE.

Keywords: genetics; risk factors; tests; thrombosis; veins.

PubMed Disclaimer

References

    1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Berqvist D, Brech JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samana MM, Spannagl Mfor the VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007; 98:756-764. - PubMed
    1. Anderson FA, Jr, Zayaruany M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007; 82:777-782. - PubMed
    1. Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin. 2011; 27:907-932. - PubMed
    1. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009; 29:943-953. - PubMed
    1. Souto JC, Almasy L, Borrell M, Blanco‐Vaca F, Mateo J, Soria JM, Coll I, Felices R, Stone W, Fontcuberta J, Blangero J. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Human Genet. 2000; 67:1452-1459. - PMC - PubMed

Publication types

MeSH terms